Evidence map›Paper›PMID 18354482›Full record

ArticleNature2008

Control of chromosome stability by the beta-TrCP-REST-Mad2 axis.

Daniele Guardavaccaro, David Frescas, N Valerio Dorrello, Angelo Peschiaroli, Asha S Multani, Timothy Cardozo, Anna Lasorella, Antonio Iavarone, Sandy Chang, Eva Hernando and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 189 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. SKP1-CUL1-F-box: Key molecular targets affecting disease progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. FBXO38 Ubiquitin Ligase Controls Centromere Integrity via ZXDA/B Stability.Frontiers in cell and developmental biology · 2022
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Daniele GuardavaccaroDepartment of Pathology, NYU Cancer Institute, New York University School of Medicine, 550 First Avenue, MSB 599, New York, New York 10016, USA.
David Frescas
N Valerio Dorrello
Angelo Peschiaroli
Asha S Multani
Timothy Cardozo
Anna Lasorella
Antonio Iavarone
Sandy Chang
Eva Hernando
Michele Pagano
New York University · USCancer Genetics (United States) · USColumbia University · USThe University of Texas MD Anderson Cancer Center · US

Funding

REGULATION OF THE GI PHASE BY THE UBIQUITIN PATHWAYR01GM057587 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 1998 to 2018
$7.8M
Howard Hughes Medical InstituteNIGMS NIH HHS R01 GM057587
6 · The paper itself

Abstract

REST/NRSF (repressor-element-1-silencing transcription factor/neuron-restrictive silencing factor) negatively regulates the transcription of genes containing RE1 sites. REST is expressed in non-neuronal cells and stem/progenitor neuronal cells, in which it inhibits the expression of neuron-specific genes. Overexpression of REST is frequently found in human medulloblastomas and neuroblastomas, in which it is thought to maintain the stem character of tumour cells. Neural stem cells forced to express REST and c-Myc fail to differentiate and give rise to tumours in the mouse cerebellum. Expression of a splice variant of REST that lacks the carboxy terminus has been associated with neuronal tumours and small-cell lung carcinomas, and a frameshift mutant (REST-FS), which is also truncated at the C terminus, has oncogenic properties. Here we show, by using an unbiased screen, that REST is an interactor of the F-box protein beta-TrCP. REST is degraded by means of the ubiquitin ligase SCF(beta-TrCP) during the G2 phase of the cell cycle to allow transcriptional derepression of Mad2, an essential component of the spindle assembly checkpoint. The expression in cultured cells of a stable REST mutant, which is unable to bind beta-TrCP, inhibited Mad2 expression and resulted in a phenotype analogous to that observed in Mad2(+/-) cells. In particular, we observed defects that were consistent with faulty activation of the spindle checkpoint, such as shortened mitosis, premature sister-chromatid separation, chromosome bridges and mis-segregation in anaphase, tetraploidy, and faster mitotic slippage in the presence of a spindle inhibitor. An indistinguishable phenotype was observed by expressing the oncogenic REST-FS mutant, which does not bind beta-TrCP. Thus, SCF(beta-TrCP)-dependent degradation of REST during G2 permits the optimal activation of the spindle checkpoint, and consequently it is required for the fidelity of mitosis. The high levels of REST or its truncated variants found in certain human tumours may contribute to cellular transformation by promoting genomic instability.

Indexed as

Chromosomal Instabilitybeta-Transducin Repeat-Containing ProteinsCalcium-Binding ProteinsCell Cycle ProteinsCell LineG2 PhaseGene Expression RegulationGenomic InstabilityHumansMad2 ProteinsMitosisProtein BindingRE1-Silencing Transcription FactorRepressor ProteinsSKP Cullin F-Box Protein LigasesSpindle Apparatusbeta-Transducin Repeat-Containing ProteinsBTRC protein, humanCalcium-Binding ProteinsCell Cycle ProteinsMAD2L1 protein, humanMad2 ProteinsRE1-Silencing Transcription FactorRepressor ProteinsSKP Cullin F-Box Protein LigasesTranscription Factors

Identifiers

PMID18354482
PMCPMC2707768
OpenAlexW1979799592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.